These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 2385743

  • 1. Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis.
    Power DA, Ng YC, Simpson JG.
    Q J Med; 1990 Apr; 75(276):387-98. PubMed ID: 2385743
    [Abstract] [Full Text] [Related]

  • 2. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC, Peters DK.
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [Abstract] [Full Text] [Related]

  • 3. Production of C3 nephritic factor by cultured lymphocytes derived from a patient with partial lipodystrophy.
    Yamada A, Ohi H, Okano K, Watanabe S, Seki M, Hatano M, Koitabashi Y.
    J Clin Lab Immunol; 1988 Sep; 27(1):35-7. PubMed ID: 3251045
    [Abstract] [Full Text] [Related]

  • 4. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M.
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [Abstract] [Full Text] [Related]

  • 5. Identification of nephritic factor as an immunoglobulin.
    Williams DG, Bartlett A, Duffus P.
    Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
    [Abstract] [Full Text] [Related]

  • 6. [Production of C3 nephritic factor by cultured lymphocytes derived from glomerulonephritic patients].
    Yamada A, Ohi H, Hatano M.
    Nihon Jinzo Gakkai Shi; 1990 Apr; 32(4):373-8. PubMed ID: 2376910
    [Abstract] [Full Text] [Related]

  • 7. [Effects of C3 nephritic factor on the complement system--with special reference to stabilizing effect on C3 convertase (C3bBb) activity (author's transl)].
    Nakanishi I.
    Nihon Jinzo Gakkai Shi; 1981 Jun; 23(6):719-32. PubMed ID: 6914399
    [No Abstract] [Full Text] [Related]

  • 8. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
    Levy Y, George J, Yona E, Shoenfeld Y.
    Immunol Res; 1998 Aug; 18(1):55-60. PubMed ID: 9724849
    [Abstract] [Full Text] [Related]

  • 9. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)].
    Lanzer G, Pogglitsch H, Tilz GP.
    Acta Med Austriaca; 1981 Aug; 8(1):7-13. PubMed ID: 6908995
    [Abstract] [Full Text] [Related]

  • 10. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M, Balow JE, Tsokos GC.
    J Immunol; 1986 Jun 15; 136(12):4451-5. PubMed ID: 3011894
    [Abstract] [Full Text] [Related]

  • 11. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
    Licht C, Fremeaux-Bacchi V.
    Thromb Haemost; 2009 Feb 15; 101(2):271-8. PubMed ID: 19190809
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.
    Servais A, Noël LH, Dragon-Durey MA, Gübler MC, Rémy P, Buob D, Cordonnier C, Makdassi R, Jaber W, Boulanger E, Lesavre P, Frémeaux-Bacchi V.
    Hum Pathol; 2011 Sep 15; 42(9):1305-11. PubMed ID: 21396679
    [Abstract] [Full Text] [Related]

  • 13. Herpes gestationis associated with the C3 nephritic factor.
    Grimwood R, Arroyave CM, Weston WL, Aeling JL.
    Arch Dermatol; 1980 Sep 15; 116(9):1045-7. PubMed ID: 6998378
    [Abstract] [Full Text] [Related]

  • 14. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.
    Gewurz AT, Imherr SM, Strauss S, Gewurz H, Mold C.
    Clin Exp Immunol; 1983 Oct 15; 54(1):253-8. PubMed ID: 6616970
    [Abstract] [Full Text] [Related]

  • 15. Anti-factor B autoantibody in dense deposit disease.
    Strobel S, Zimmering M, Papp K, Prechl J, Józsi M.
    Mol Immunol; 2010 Apr 15; 47(7-8):1476-83. PubMed ID: 20193965
    [Abstract] [Full Text] [Related]

  • 16. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V.
    Kidney Int; 2017 Nov 15; 92(5):1232-1241. PubMed ID: 28712854
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. C3 nephritic factor and SLE: report of four cases and review of the literature.
    Walport MJ, Davies KA, Botto M, Naughton MA, Isenberg DA, Biasi D, Powell RJ, Cheung NT, Struthers GR.
    QJM; 1994 Oct 15; 87(10):609-15. PubMed ID: 7987656
    [Abstract] [Full Text] [Related]

  • 19. Nucleotide sequence of a human autoantibody to the alternative pathway C3/C5 convertase (C3NeF).
    Victor KD, Pascual V, Stitzel AE, Tsokos GC, Capra JD, Spitzer RE.
    Hybridoma; 1993 Jun 15; 12(3):231-7. PubMed ID: 8395463
    [Abstract] [Full Text] [Related]

  • 20. [Complement and nephritic activity in membranoproliferative glomerulonephritis].
    Lévy M, Sich M, Habib R.
    Arch Fr Pediatr; 1979 Nov 15; 36(9 Suppl):LXIV-LXXIV. PubMed ID: 539879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.